|
Name |
cis-2-Pinanol
|
Molecular Formula | C10H18O | |
IUPAC Name* |
(1R,2S,5S)-2,6,6-trimethylbicyclo[3.1.1]heptan-2-ol
|
|
SMILES |
C[C@@]1(CC[C@H]2C[C@@H]1C2(C)C)O
|
|
InChI |
InChI=1S/C10H18O/c1-9(2)7-4-5-10(3,11)8(9)6-7/h7-8,11H,4-6H2,1-3H3/t7-,8+,10-/m0/s1
|
|
InChIKey |
YYWZKGZIIKPPJZ-XKSSXDPKSA-N
|
|
Synonyms |
cis-2-Pinanol; 4948-28-1; 2-Pinanol, cis-; Bicyclo(3.1.1)heptan-2-ol, 2,6,6-trimethyl-, (1R,2S,5S)-rel-; 2J3SJ3OQEU; (1R,2S,5S)-2,6,6-trimethylbicyclo[3.1.1]heptan-2-ol; trans-Pinene hydrate; (1-alpha,2-alpha,5-alpha)-2,6,6-Trimethylbicyclo(3.1.1)heptan-2-ol; Pinan-2-alpha-ol; Caswell No. 663L; UNII-2J3SJ3OQEU; EINECS 225-591-4; PINAN-2.ALPHA.-OL; DTXSID3027582; DTXSID501046080; ZINC5497257; 2,6,6-Trimethylbicyclo(3.1.1)heptan-2-ol, (1alpha,2alpha,5alpha)-; 2-PINANOL, CIS-(+/-)-; Bicyclo(3.1.1)heptan-2-ol, 2,6,6-trimethyl-, (1alpha,2alpha,5alpha)-; Q27254811; (1alpha,2alpha,5alpha)-2,2,6-Trimethylbicyclo(3.1.1)heptan-2-ol; Bicyclo(3.1.1)heptan-2-ol, 2,6,6-trimethyl-, (1-alpha,2-alpha,5-alpha)-
|
|
CAS | 4948-28-1 | |
PubChem CID | 6428289 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 154.25 | ALogp: | 2.1 |
HBD: | 1 | HBA: | 1 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 20.2 | Aromatic Rings: | 3 |
Heavy Atoms: | 11 | QED Weighted: | 0.568 |
Caco-2 Permeability: | -4.458 | MDCK Permeability: | 0.00002180 |
Pgp-inhibitor: | 0.028 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.01 |
30% Bioavailability (F30%): | 0.312 |
Blood-Brain-Barrier Penetration (BBB): | 0.476 | Plasma Protein Binding (PPB): | 51.01% |
Volume Distribution (VD): | 1.051 | Fu: | 55.00% |
CYP1A2-inhibitor: | 0.064 | CYP1A2-substrate: | 0.365 |
CYP2C19-inhibitor: | 0.063 | CYP2C19-substrate: | 0.87 |
CYP2C9-inhibitor: | 0.053 | CYP2C9-substrate: | 0.271 |
CYP2D6-inhibitor: | 0.007 | CYP2D6-substrate: | 0.387 |
CYP3A4-inhibitor: | 0.032 | CYP3A4-substrate: | 0.282 |
Clearance (CL): | 11.031 | Half-life (T1/2): | 0.488 |
hERG Blockers: | 0.011 | Human Hepatotoxicity (H-HT): | 0.061 |
Drug-inuced Liver Injury (DILI): | 0.025 | AMES Toxicity: | 0.003 |
Rat Oral Acute Toxicity: | 0.127 | Maximum Recommended Daily Dose: | 0.675 |
Skin Sensitization: | 0.283 | Carcinogencity: | 0.062 |
Eye Corrosion: | 0.989 | Eye Irritation: | 0.986 |
Respiratory Toxicity: | 0.956 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000790 | 0.439 | D0H1QY | 0.381 | ||||
ENC001893 | 0.412 | D0V8HA | 0.356 | ||||
ENC002124 | 0.396 | D07QKN | 0.271 | ||||
ENC002256 | 0.385 | D0U3GL | 0.250 | ||||
ENC002222 | 0.385 | D04CSZ | 0.234 | ||||
ENC000653 | 0.381 | D0Q6NZ | 0.234 | ||||
ENC000481 | 0.381 | D0Z1XD | 0.233 | ||||
ENC002232 | 0.381 | D08QKJ | 0.228 | ||||
ENC002662 | 0.375 | D00VZZ | 0.224 | ||||
ENC005519 | 0.372 | D0L2LS | 0.221 |